

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 January 2024 (25.01.2024)



(10) International Publication Number
WO 2024/020468 A1

(51) International Patent Classification:

A61K 31/4245 (2006.01) A61K 45/00 (2006.01)
A61K 31/4402 (2006.01) A61P 9/00 (2006.01)
A61K 9/00 (2006.01) A61P 9/04 (2006.01)

(21) International Application Number:

PCT/US2023/070533

(22) International Filing Date:

19 July 2023 (19.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/368,967	20 July 2022 (20.07.2022)	US
63/375,026	08 September 2022 (08.09.2022)	US
63/486,594	23 February 2023 (23.02.2023)	US
63/491,010	17 March 2023 (17.03.2023)	US
63/495,966	13 April 2023 (13.04.2023)	US
63/501,088	09 May 2023 (09.05.2023)	US

(71) Applicant: **CYTOKINETICS, INCORPORATED**
[US/US]; 350 Oyster Point Blvd, South San Francisco, California 94080 (US).

(72) Inventors: **HEITNER, Stephen B.**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd, South San Francisco,

California 94080 (US). **MALIK, Fady**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd, South San Francisco, California 94080 (US). **KUPFER, Stuart**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd, South San Francisco, California 94080 (US). **JACOBY, Daniel Louis**; c/o Cytokinetics, Incorporated, 350 Oyster Point Blvd, South San Francisco, California 94080 (US).

(74) Agent: **DAWSON, Thomas K.** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

(54) Title: METHODS FOR TREATING NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY




FIG. 1

(57) Abstract: Methods for treating non-obstructive hypertrophic cardiomyopathy or hypertrophic cardiomyopathy with mid-ventricular obstruction (MVO) are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) and may include titrating an administered daily dose based on a component of an echocardiogram. The daily dose may be increased, maintained, or decreased, or terminated, based on the echocardiogram.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))